



Healthcare-Associated Infection Mini-Summit

Thursday, December 10th, 2020 • 12:00 PM – 3:30 PM EST

12:00 PM – 12:10 PM EST	Intro to the Day and Patient Story <p style="text-align: right;">Cindy Hou DO, MA, MBA, FACOI, FACP, FIDSA Infection Control Officer, Jefferson Health New Jersey</p> <p style="text-align: right;">Mary Miller, RN, BSN, CIC Jefferson Health New Jersey</p>
12:10 PM – 12:40 PM EST	Sepsis in the Context of Nonventilator Hospital-Acquired Pneumonia <p style="text-align: right;">Dian Baker PhD, RN Professor, School of Nursing California State University, Sacramento</p>
12:40 PM – 1:10 PM EST	Ventilator-Associated Pneumonia Prevention Pitfalls <p style="text-align: right;">Michael Klompas MD, MPH Hospital Epidemiologist, Brigham and Women’s Hospital</p>
1:10PM – 1:15PM EST	BREAK
1:15 PM – 1:45 PM EST	Clostridioides Difficile Infection <p style="text-align: right;">Alice Guh, MD, MPH, FIDSA Medical Officer, CDC, Division of Healthcare Quality Promotion</p>
1:45 PM – 2:15 PM EST	Antimicrobial Therapy for Intra-Abdominal Infection <p style="text-align: right;">John Mazuski, MD, PhD Professor of Surgery, Washington Univ School of Medicine in St. Louis</p>
2:15PM – 2:20PM EST	BREAK
2:20 PM – 2:50 PM EST	Cardiac Implantable Electronic Device Infection <p style="text-align: right;">Uzma Syed, DO, FIDSA Director of Antimicrobial Stewardship Center of Excellence, Good Samaritan Hospital Medical Center</p>
2:50 PM – 3:20 PM EST	Prevention of Prosthetic Joint Infections <p style="text-align: right;">Cindy Hou DO, MA, MBA, FACOI, FACP, FIDSA Infection Control Officer, Jefferson Health New Jersey</p>
3:20 PM – 3:30 PM EST	Conclusion/Ending Comments

This event is supported by an unrestricted medical education grant from Merck to Sepsis Alliance. All event speakers are participating on a voluntary basis; participation does not indicate a relationship between the speakers and Merck or other Sepsis Alliance supporters.



Healthcare-Associated Infection Mini-Summit

Presentation Descriptions

Sepsis in the Context of Nonventilator Hospital-Acquired Pneumonia

12:10 PM – 12:40 PM EST

Dian Baker PhD, RN

Non-ventilator healthcare associated pneumonia (NVHAP) is one of the most common healthcare acquired infections in the U.S. NVHAP is potentially preventable and places an estimated 35 million patients at risk with over \$3 billion in predicted healthcare costs annually. Pneumonia is the most common source of sepsis and therefore efforts to address NVHAP prevention may also impact the incidence of sepsis.

Ventilator-Associated Pneumonia Prevention Pitfalls

12:40 PM – 1:10 PM EST

Michael Klompas MD, MPH

Patients who are critically ill and require mechanical ventilation are at risk to develop ventilator-associated pneumonia (VAP). Morbidity and mortality for patients with VAP is significant. Learn about potential strategies to prevent ventilator associated pneumonia and identify the prevention practices most effective to improve objective outcomes in mechanically ventilated patients. In addition, information to help recognize potential sources of bias when evaluating VAP prevention studies will be discussed.

Clostridioides Difficile Infection

1:15 PM – 1:45 PM EST

Alice Guh, MD, MPH

This presentation will describe the epidemiology of Clostridioides difficile infection (CDI) in the United States and the use of epidemiological data to drive CDI prevention. In addition, the presentation will discuss CDI diagnostic testing and associated challenges as well as review updated CDI treatment recommendations.

Antimicrobial Therapy for Intra-Abdominal Infection

1:45 PM – 2:15 PM EST

John Mazuski, MD, PhD

Intra-abdominal infection is managed by judicious correction of abnormal physiological parameters, source control procedures to treat the cause of the infection, and antimicrobial therapy as an adjunct to source control to eradicate residual pathogens. Empiric antimicrobial therapy should be individualized according to the patient's overall risk of treatment failure and the likelihood of harboring resistant pathogens. Principles of antimicrobial stewardship applicable to intra-abdominal infection include use of appropriate empiric agents, de-escalation of broad-spectrum therapy when possible, and short duration in patients with adequate source control.

Cardiac Implantable Electronic Device Infection

2:20 PM – 2:50 PM EST

Uzma Syed, DO, FIDSA

Overview of the definition and pathogenesis of cardiovascular implantable electronic device infections. The risk factors, microbiological causative agents, diagnosis and treatment will be reviewed. Infection prevention and antimicrobial stewardship interventions will be reviewed. Attendees will learn to: identify risk factors for patients who develop cardiovascular implantable electronic device infections; differentiate pocket infection from systemic infection; identify laboratory and imaging modalities needed to definitively diagnose CIED; and identify treatment strategies.

Prevention of Prosthetic Joint Infections

2:50 PM – 3:20 PM EST

Cindy Hou DO, MA, MBA, FACOI, FACP, FIDSA

In this session, we will review prosthetic joint infection from the perspectives of infection prevention and antibiotic stewardship. The development of prosthetic joint infections impacts patients -- potentially requiring additional surgeries and antibiotics, which is why prevention is paramount. At the patient level, there are factors that can be medically optimized and strategies for decolonization of bacteria prior to operations involving placement of prostheses. Prior to insertion, providers order antibiotics for surgical prophylaxis.